The impact of COVID-19 on the practice of Oral and Maxillofacial Pathology in the United States and Canada.

BACKGROUND: The COVID-19 pandemic has significantly disrupted the delivery of healthcare, including oral healthcare services. The restrictions imposed for mitigating spread of the virus forced dental practitioners to adopt significant changes in their workflow pattern. The aim of this study was to investigate the impact of the pandemic on the practice of oral and maxillofacial pathology in two countries in regard to educational activities, and clinical and diagnostic pathology services. MATERIAL AND METHODS: An online questionnaire was distributed to oral and maxillofacial pathologists in the United States and Canada. The survey was designed by combining dichotomous, multiple choice, and Likert response scale questions. Statistical analysis of the collected data was performed with SPSS software. RESULTS: Most pathologists, at the time of survey completion, were teaching synchronously, primarily with case-based learning and live lectures. During lockdown, 52.4% and 50.0% of those with trainees expected their residents to show up for clinic- and laboratory-related procedures respectively. The pathologists were most concerned for their residents' inadequate clinical exposure, future placement, and face-to-face teaching time. About 89.0% pathologists were able to provide emergent care, with 82.4% and 23.5% having performed telehealth consultations and oral biopsy procedures, respectively. During the lockdown, the pathology laboratories for 90.9% of participants received biopsy specimens that predominantly comprised of potentially malignant or malignant lesions. However, a reduction in the number of biopsy submissions was reported. CONCLUSIONS: Given the challenges of the pandemic, oral and maxillofacial pathologists in the United States and Canada successfully continued their pursuits in education, clinical care, and diagnostic pathology services.

Isolation of a new broad spectrum antifungal polyene from Streptomyces sp. MTCC 5680.

UNLABELLED: A new polyene macrolide antibiotic PN00053 was isolated from the fermentation broth of Streptomyces sp. wild-type strain MTCC-5680. The producer strain was isolated from fertile mountain soil of Naldehra region, Himachal Pradesh, India. The compound PN00053 was purified through various steps of chromatographic techniques and bio-activity guided fractionation followed by its characterization using physiochemical properties, spectral data ((1) H-NMR, (13) C-NMR, HMBC, HSQC, and COSY) and MS analysis. PN00053 exhibited broad spectrum in vitro antifungal activity against strains of Aspergillus fumigatus (HMR), A. fumigatus ATCC 16424, Candida albicans (I.V.), C. albicans ATCC 14503, C. krusei GO6, C. glabrata HO4, Cryptococcus neoformans, Trichophyton sp. as well as fluconazole resistant strains C. krusei GO3 and C. glabrata HO5. It did not inhibit growth of gram positive and gram-negative bacteria, displaying its specificity against fungi. SIGNIFICANCE AND IMPACT OF THE STUDY: PN00053 is a novel polyene macrolide isolated from a wild strain of Streptomyces sp. PM0727240 (MTCC5680), an isolate from the mountainous rocky regions of Himachal Pradesh, India. The compound is a new derivative of the antibiotic Roflamycoin [32, 33-didehydroroflamycoin (DDHR)]. It displayed broad spectrum antifungal activity against yeast and filamentous fungi. However, it did not show any antibacterial activity. The in vitro study revealed that PN00053 has better potency as compared to clinical gold standard fluconazole. The development of pathogenic resistance against the polyenes has been seldom reported. Hence, we envisage PN00053 could be a potential antifungal lead.